Our Pipeline

HeFH, a form of familial hypercholesterolemia, is a genetic disease characterized by extremely high LDL-C levels in the blood as well as heart attack and/or stroke at an early age. Approximately 3 million people in the U.S. and Europe suffer from this genetic disease.

Atherosclerotic cardiovascular disease is a large subset of cardiovascular disease, where cholesterol-driven blockages in arteries lead to complications such as heart attack, stroke or limb amputations. Approximately 54 million people in the U.S. and Europe are affected by ASCVD.

HeFH, a form of familial hypercholesterolemia, is a genetic disease characterized by extremely high LDL-C levels in the blood as well as heart attack and/or stroke at an early age. Approximately 3 million people in the U.S. and Europe suffer from this genetic disease.

Atherosclerotic cardiovascular disease is a large subset of cardiovascular disease, where cholesterol-driven blockages in arteries lead to complications such as heart attack, stroke or limb amputations. Approximately 54 million people in the U.S. and Europe are affected by ASCVD.

HoFH, a form of familial hypercholesterolemia, is a rare genetic disease characterized by premature heart attack and/or stroke due to extremely high LDL-C levels, often greater than 500 mg/dL. It impacts approximately 2,800 people in the U.S. and Europe. 

Refractory hypercholesterolemia refers to patients with ASCVD who are not at their medically recommended LDL-C goal despite taking an oral therapy and a PCSK9 inhibitor to lower LDL-C. Approximately 13% of people with ASCVD fall into this category.

Approximately 20% of patients with ASCVD have elevated Lp(a), impacting an estimated 11 million people in the U.S. and Europe.